Somatic mutations and immune checkpoint biomarkers.

Area of Science:

• Oncology
• Molecular Diagnostics
• Personalized Medicine

Background:

• Molecular testing for somatic mutations and immune checkpoint biomarkers is crucial for personalized non-small cell lung cancer (NSCLC) treatment.
• Clinical molecular testing choices depend on cost, expertise, instrumentation, and sample availability.
• Tumor cells exploit the programmed death ligand-1 (PD-L1) pathway for immune resistance, necessitating accurate biomarker identification.

Purpose of the Study:

• To review various molecular testing techniques used in clinical settings for non-small cell lung cancer.
• To discuss the advantages and limitations of each technique in identifying targetable alterations and immune biomarkers.
• To explore the future trends in molecular platforms for guiding NSCLC patient management.

Main Methods:

• Immunohistochemistry (IHC) for classifying histology and identifying targetable alterations (EGFR, ALK, PD-L1).
• Direct sequencing, historically used for EGFR, KRAS, and BRAF mutations.
• Real-time polymerase chain reaction (PCR) as a cost-effective single-gene test.
• Next-generation sequencing (NGS) for high-throughput analysis of multiple genes, including rare mutations.

Main Results:

• IHC is standard for EGFR, ALK, and PD-L1 assessment, informing immune checkpoint inhibitor therapy.
• Direct sequencing has been largely replaced by more sensitive methods.
• NGS offers comprehensive mutation profiling, detecting common and rare genetic alterations.
• PCR-based methods provide efficient, cost-effective single-gene testing when NGS is unavailable.

Conclusions:

• The selection of molecular testing methods is critical for effective personalized treatment of NSCLC.
• Emerging techniques like NGS are expanding the scope of molecular profiling in NSCLC.
• Standardized assays and continued innovation in molecular platforms are essential for optimizing clinical management and patient outcomes.